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Letter to the EditorReduced immunoglobulin gene
diversity in patients with
Cornelia de Lange syndromeTo the Editor:
B cells rely on a broad receptor repertoire to provide protection
against a wide range of pathogens. This is in part achieved
through V(D)J recombination, which, by assembling various
combinations of variable (V), diversity (D), and joining (J) genes,
creates different IgV regions.1 The recombination processes is
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 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy, Asthma & Immunology. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).enzymes and requires a functional nonhomologous end-joining
(NHEJ) machinery. B cells can further diversify their IgV regions
through somatic hypermutation (SHM) to improve affinity
between the antibody and antigen and switch the isotype of
antibody produced by class-switch recombination (CSR). Both
processes are initiated by activation-induced cytidine deaminase
(AID) and rely on transcription and a number of DNA repair
mechanisms.
Cornelia de Lange syndrome (CdLS) is a rare multisystem
developmental disorder characterized by typical facial features,
intellectual disability, and multiple congenital anomalies.2 Most
patients with CdLS have deleterious mutations in the gene
encoding the cohesin loader Nipped-B-like (NIPBL), but
mutations in the other cohesin-related genes SMC1A, SMC3,
PDS5B, RAD21, or HDAC8 have also been identified in selectedoximal IGHV genes in patients with CdLS. A and B,
tion of unique B-cell clones (Fig 1,B) that account for
ues: **P < .01 and ***P < .001, Student t test. Each
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ly.
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FIG 2. Mutation frequency and substitution pattern in IGHV regions from NIPBL1/2 and SMC1A2 B cells. A,
Mutation frequencies are shown at left. Each dot represents 1 subject. Black or white squares indicate
NIPBL1/2 patients with a classical or mild form of disease, respectively. Percentages of sequences with 0,
1 to 5, 6 to 10, or more than 10 mutations in the IGHV regions from control, NIPBL1/2, or SMC1A2 cells
are depicted in pie charts at right. IGHV1-18, IGHV1-69, IGHV3-23, IGHV3-30, IGHV3-33, and IGHV4-34
sequences were included in the analysis. Significant differences compared with control values: *P < .05,
Student t test. B, Frequencies of substitutions in the IGHV genes (x2 test, Bonferroni corrected). C, Frequency
of mutations within W(A/T)R(G/A)CY(C/T)/RGYW motifs in the IGHV genes analyzed in Fig 2, A. Asterisks
indicate significant differences between NIPBL1/2 (black asterisks) and SMC1A2 (gray asterisks) compared
with control cells. *P < .05, x2 test, Bonferroni corrected.
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chromatid cohesion, transcription, long-range gene interactions,
and DNA repair.3
Aberrant CSR patterns have been observed in B cells from
patients with NIPBL mutations.4 Here we further investigated
whether V(D)J recombination or SHM is affected in patients
with CdLS. In chromosome-integrated V(D)J reporter assays,a reduced substrate recombination efficiency was observed in
NIPBL knockdown human fibroblast or murine pro-B cells (see
Fig E1 and theMethods section in this article’s Online Repository
at www.jacionline.org).
We next analyzed the IGH repertoire in 5 patients with
NIPBL mutations and 3 patients with SMC1A mutations
with CdLS (see Table E1 in this article’s Online Repository at
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repertoire, which is estimated by either the proportion of
sequences with a unique complementary determining region 3
(CDR3) divided by the total number of sequences or by
cumulative 50% of the total CDR3s in the samples (diversity 50
[D50]), which is a measurement of the evenness of the
distribution of B-cell clones, was significantly lower in patients
with NIPBL or SMC1A mutations (Fig 1, A and B). Thus the
patients with CdLS had a reduced overall diversity of their
IGHV regions, with an overrepresentation of large B-cell clones.
Furthermore, in patients with NIPBL mutations with the
classical form of the disease and in patients with SMC1A
mutations, the frequency of IGHV genes located in the most
proximal one third of the IGH locus (about 250 kb) was increased
(Fig 1, C, and see Fig E2 in this article’s Online Repository at
www.jacionline.org). The observed skewed pattern of VH genes
in the patients is likely to be a result of B cell–intrinsic
changes because only sequences resulting from unproductive
rearrangement (successfully rearranged but out of reading frame
or containing stop codons) were included in this analysis, and an
influence of antigen selection can thus be excluded.
The overall mutation frequency in the unproductive and most
commonly mutated IGHV genes was also reduced in the patients
with CdLS, reaching statistical significance for the group with an
NIPBL mutation (Fig 2, A). The proportion of unmutated
sequences was increased in the patients with NIPBL mutations,
especially in those with the classical form of the disease (Fig 2,
A). However, the pattern of base pair substitution in the V regions
was largely normal in the patients (Fig 2, B).
Our data suggest that the cohesion-associated proteins NIPBL
and SMC1A are involved in regulation of V(D)J recombination in
human B cells, possibly through regulation of locus contraction.
Increased use of proximally located IghV genes has previously
been observed in mice deficient in factors associated with locus
contraction, such as Ikaros, Yin Yang 1, and Pax5, and the cohesin
interaction partner CCCTC-binding factor has been suggested to
regulate locus contraction and V(D)J recombination at the mouse
Igh locus.5-7
Another possible explanation of how NIPBL/SMC1A could
affect V(D)J recombination could be a change in regulation of
DNA repair. We have previously observed a correlation between
heterozygous NIPBL loss-of-function mutations and increased
sensitivity to g-radiation and a shift toward use of
microhomology-based end-joining during CSR, suggesting that
NIPBL regulates the NHEJ process.4 However, the V(D)J coding
junctions generated in vivo in patients with CdLS showed a
normal repair pattern (see Table E2 in this article’s Online
Repository at www.jacionline.org). Furthermore, expression of
a number of key V(D)J recombination factors was largely normal
in NIPBL knockdown cells (see Fig E3, B, in this article’s Online
Repository at www.jacionline.org). Thus the core NHEJ
machinery appears to be retained in patients with CdLS.
We also found a reduced frequency of mutations within the
IGHV regions in patients with CdLS. NIPBL and SMC1A could
both be involved in the SHM process through regulation of
transcription or RNA polymerase pausing, which promotes
formation of single-stranded DNA and AID targeting. In support
of this notion, there was a reduced number of mutations observed
in the RGYW motifs (containing the AID hotspot in the bottom
strand) in NIPBL1/2 and SMC1A2 cells, suggesting an impaired
mutagenesis of C residues on the bottom strand (Fig 2, C).We have previously observed the opposite pattern in NBS1-
deficient cells.8 Thus the targeting of AID and/or linked repair
seem to be asymmetric during SHM, and this can be regulated
by a number of factors, including the cohesin-associated factors.
CdLS is not traditionally considered an immunodeficiency
disorder, but these patients have an increased prevalence of
severe infections.9 Immunodeficiency, including mild B-cell
lymphopenia, reduced switched memory B-cell numbers, and/or
reduced serum immunoglobulin levels, has been observed in
previous case reports9 and in our own patients (see Table E3 in
this article’s Online Repository at www.jacionline.org). Complete
knockout of NIPBL is incompatible with survival, and
heterozygous nonsense mutation or frameshift deletions in NIPBL
are usually associated with a more severe clinical phenotype than
those with missense mutations and in frame deletions (classical vs
mild form), suggesting a dose-dependent role of the cohesin-
associated proteins. The SMC1A mutations are missense or
in-frame deletions and are generally associated with a milder
CdLS phenotype. Thus mutations identified in patients with CdLS
can be considered hypomorphic and/or result in haploinsufficiency,
and a more significant alteration in immunoglobulin gene diversifi-
cations and a more severe immunodeficiency would be expected in
the event of a complete loss of these cohesin-associated proteins.
In summary, the less diversified VH genes caused by reduced
efficiency of V(D)J recombination together with inefficient
CSR efficiency might contribute to the frequent infections in
patients with CdLS.
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METHODS
Patients
Eight patients with CdLS were included in the study (Table E1). Five had
heterozygous mutations in theNIPBL gene, 2 of whom (P3 and P6) had amore
severe classical form of CdLS, whereas 3 (P8, P10, and P11) had amilder form
of disease. In addition, 3 male patients had mutations within the SMC1A gene,
which was located on the X-chromosome (SMC1A-1, SMC1A-2, and
SMC1A-4). The clinical features of 7 of the 8 patients have been described
previously.E1-E4 Seven unaffected control subjects were also included in the
study (Table E1). DNA was isolated from peripheral blood by using
standard methods. The study was approved by the institutional review board
at the Karolinska Institutet.
V(D)J recombination substrate assays for
assessment of recombination efficiency
The retroviral vector pMX-RSS–green fluorescent protein (GFP)/internal
ribosomal entry site (IRES)–hCD4 (MX-RSS-INV), which contains an
antisense-orientated RSS-flanked enhanced GFP reporter and an
IRES-linked human CD4 cassette,E5 was transduced into HEK293FT cells
together with 3 viral packaging vectors (pGag-Pol, pRev, and pVSV-G) by
using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, Mass).
Forty-eight hours later, the medium containing virus was collected and used
to infect the human fibroblast cell line from an unaffected control subject.
Seventy-two hours later, the transduced cells were sorted by means of flow
cytometry with human CD4 antibody (BioLegend, San Diego, Calif). The
CD41 cells were expanded in culture for 4 days and then seeded into 6-well
plates (105 cells per well) and treated with either NIPBL or control small
interfering RNA (siRNA; GE Dharmacon, Lafayette, Colo)E4 for 48 hours.
The cells were subsequently transfected with 0.9 mg of RAG1 and 0.75 mg
of RAG2 plasmids by using TurboFect (Fermentas, Waltham, Mass).
Forty-eight hours after transfection, cells were collected, and recombination
activity was assessed as percentages of GFP1 cells by using flow cytometry.
This chromosome-integrated reporter assay allows assessment of V(D)J
recombination and infection efficiency through measurement of expression
of GFP or CD4, respectively. Gene knockdown efficiency was monitored by
using real-time PCR (see Fig E1, B), as described previously.E4
A murine B-abl pro-B-cell line (with a Bcl2 transgene) carrying the
chromosome-integrated MX-RSS-INV substrate was previously described.E6
Cells were treated with either Nipbl or control smart pool mouse siRNA
(GE Dharmacon) by using a Nucleofector Kit (Lonza, Basel, Switzerland)
for 48 hours and then treated with 0.3 mmol/L abl kinase inhibitor
(PD-180970; Sigma-Aldrich, St Louis, Mo), which leads to G1 cell-cycle
arrest and an induction/stabilization of expression of RAG1/RAG2.E7
Recombination activity was subsequently assessed as a percentage of GFP1
cells by using flow cytometry. Gene knockdown efficiency was monitored
by means of real-time PCR (Fig E1, C).
Amplification and high-throughput sequencing of
IGHV regions from patients with CdLS
Immunoglobulin genes were amplified by using a seminested PCR, as
previously described,E8 with the exception that 100 ng of genomic DNA and
250 nmol/L of each downstream IGHJ primer were used in the PCR reaction.
Sequencing was performed on the Roche 454 GS FLX Titanium Sequencer
(Agowa GmbH, Berlin, Germany). V-QUEST,E9,E10 allowing detection of
indels, was used to determine the amino acid sequence of CDR3, as well as
the V, D, and J genes used. Sequences not spanning the V(D)J junction
were removed, and the remaining sequences were used in subsequent
analyses. Therefore any large deletions that resulted in missing an entire
CDR3 would not be recorded. The D50 value was calculated by dividing
X by Y and multiplying by 100, where X is the number of unique CDR3s
that account for the cumulative 50 percent of the total sequences and Y is
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number of unique CDR3s. A sample with an equal distribution of all clones
would have a D50 of 50, whereas a number less than 50 indicates the presence
of uneven larger clones.E11 Chimeric sequences, which are artifacts created
during the PCR reaction that contains more than 1 IGHV region, were detected
by means of visual inspection. If the sequence matched more than 1 IGHV
gene at either end, the sequence was omitted from IGHV gene use analysis.
For SHM analysis, chimeric sequences were also omitted, unless the sequence
was chimeric at the first half of the IGHV region sequence, when the remaining
part was still included in the analysis. Only unique and unproductive
sequences (VH and JH genes are not in the same reading frame or containing
premature stop codons) were included for the VH gene use and SHM analyses
to avoid any antigen selection bias from the expressed repertoire. The error
rate of 454 sequencing was previously determined to be less than 1 error
per 1300 bp when indels were excluded.E8
Real-time PCR
One microgram of total RNAwas used to synthesize cDNA, according to
the manufacturer’s protocol (cDNA synthesis kit; GE Healthcare, Piscataway,
NJ). Expression of human XRCC6, LIG4, DCLRE1C, PRKDC, or NIPBL in
the fibroblast cell line treated with control or NIPBL siRNAwas determined
by means of quantitative real-time PCR assays with a similar setting, as
described previously.E4 Primer sequences are available on request. Briefly,
real-time PCR amplification was performed with the Kapa SYBR Fast
qPCR Master Mix Kit (Kapa Biosystems, Wilmington, Mass). ACTB was
used as a housekeeping gene for calculation of relative expression levels.
Expression of Nipbl in the murine B-abl pro-B-cell line treated with control
or Nipbl siRNA was determined by using a similar strategy, with mouse
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) as the housekeeping
gene.
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FIG E1. V(D)J recombination substrate assays in a human fibroblast cell line and a murine pro-B-cell line.
A, Schematic picture of the pMX-RSS-GFP/IRES-hCD4 (MX-RSS-INV) construct. EGFP, Enhanced GFP; LTR,
long terminal repeat. B and C, Expression of NIPBL in a human fibroblast line stably transfected with the
MX-RSS-INV construct (Fig E1, B) and expression of Nipbl in a mouse pro-B-cell line stably transfected
with the same construct (Fig E1, C) were measured by using real-time PCR. Expression of NIPBL or Nipbl
was reduced by 19% or 36% with the scrambled control siRNAs and by 80% or 74% after specific NIPBL
or Nipbl siRNA treatment. RQ, Relative quantification. D, Chromosome-integrated V(D)J reporter assay in
human fibroblast cells. The V(D)J reporter MX-RSS-INV was retrovirally transduced into a human fibroblast
cell line from an unaffected control. CD41 cells were sorted by means of fluorescence-activated cell sorting
and expanded and tested (see the Methods section in this article’s Online Repository). GFP1 cells are
indicative of successful recombination. Statistical calculation was performed with the Student t test. Results
represent 2 independent experiments. E, V(D)J reporter assay in a murine B-Abl pro-B-cell line carrying the
chromosome integrated MX-RSS-INV substrate. GFP1 cells are indicative of successful recombination.
Statistical calculation was performed with the Student t test. Results represent 2 independent experiments.
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FIG E2. Frequencies of individual IGHV genes in unproductive sequences in classical NIPBL (A) and
SMC1A-mutated (B) B cells from patients with CdLS are shown. Statistical calculations were performed
by using the Student t test, and significant differences compared with control values are indicated by
arrows. [ and Y, Increased or decreased compared with control values, respectively.
J ALLERGY CLIN IMMUNOL
VOLUME nnn, NUMBER nn
LETTER TO THE EDITOR 4.e3
FIG E3. Expression of gene analysis in NIPBL knockdown cells. A, Expression of NIPBL in a human
fibroblast line was measured by using real-time PCR. NIPBL expression was reduced by 21% with the
scrambled control siRNAs and by 77% after specific NIPBL siRNA treatment. B, Expression of genes
involved in V(D)J recombination in a human fibroblast cell line. Results represent an average of 2
independent experiments. (-), Untreated; Ctrl, control; RQ, relative quantification.
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TABLE E1. Patients included in the study
Patient Age/sex Mutation Diagnosis Total seq
Productive/
unproductive ratio*
Seq with
unique CDR3 Diversityy
Unproductive
seq with unique
CDR3 but not chimericz Reference
P3 17 y/F NIPBL1/2, c.6250_6255del, p.V2084-V2085, deletion Classical CdLS 806 0.69/0.31 475 0.59 125 E2, E4
P6 2 y/M NIPBL1/2, c.4593T>A, p.Y1531X, nonsense Classical CdLS 1,874 0.68/0.32 1,091 0.58 374 E2, E4
P8 4 y/F NIPBL1/2, c.4321G>T, p.V1441L, splice site§ Mild CdLS 11,776 0.66/0.34 7,070 0.60 1,938 E1, E4
P10 10 y/M NIPBL1/2, c.6242G>C, p.G2081A, missense Mild CdLS 2,261 0.66/0.34 1,386 0.61 360 E1, E4
P11 14 y/M NIPBL1/2, c.8387A>G, p.Y2796C, missense Mild CdLS 1,191 0.64/0.36 675 0.57 215 This report
SMC1A-1 2 y/M SMC1A2, c.587G>A, p.R196H, missense CdLS 2,497 0.66/0.34 1,489 0.60 405 E3, E4
SMC1A-2 5 y/M SMC1A2, c.3254A>G, p.Y1085C, missense CdLS 3,308 0.68/0.32 2,022 0.61 550 E3, E4
SMC1A-4 9 y/M SMC1A2, c.3568A>G, p.K1190E, missense CdLS 2,163 0.66/0.34 1,390 0.64 402 E4
C19 19 y/M — Unaffected 276 0.62/0.38 210 0.76 41 This report
C31 19 y/? — Unaffected 316 0.62/0.38 257 0.81 71 This report
C34 13 y/? — Unaffected 660 0.65/0.35 506 0.77 113 This report
C54 13 y/? — Unaffected 1,840 0.63/0.37 1,272 0.69 321 This report
gContk 2 y, 5 y, 7 y/? — Unaffected 3,482 0.53/0.47 2,845 0.82 1,033 This report
F, Female; M, male; Seq, sequence.
*Productive: As a result of V(D)J recombination, the VH, DH, and JH genes are in the correct translational reading frame.
Diversity was calculated by dividing sequences with unique CDR3s with the total sequences. Sequences not spanning the CDR3 region were omitted from calculation.
Only unproductive rearrangement (out of reading frame or containing a stop codon): unique sequences that are not chimeric at both ends were included in V gene analysis.
§This mutation has been shown to yield 2 transcripts, of which one bears an exon 20 deletion and the other is of ordinary size but with a V1441L change.E1
kgCont, Contains a pool of DNA from 3 subjects.
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TABLE E2. Characterization* of in vivo–generated V(D)J coding junctionsy
Study groups Average CDR3 lengths (bp) Average no. of palindromic nucleotides (bp) Average no. of nontemplate nucleotides (bp)
NIPBL1/2 53.1 0.46 13.5
SMC1A2 53.5 0.50 14.5
Control subjects 53.1 0.48 14.2
*Statistical calculations were performed by using the Student t test. No significant differences were found.
Calculations were based on unique sequences.
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TABLE E3. Immunologic data of patients P6, P8, P10, P11, SMC1A-1, and SMC1A-2 with CdLS
P6 (classical CdLS) P8 (mild CdLS) P10 (mild CdLS) P11 (mild CdLS) SMC1A-1 SMC1A-2
Age at sampling (y) 14 4 10 14 8 11
Lymphocytes*
Proportion of
lymphocytes
31% (22% to 50%) NA 35.5% (20% to 45%) 33.4% (20% to 45%) NA NA
Total lymphocytes 2100 mm3 (1000-5500 mm3) NA 1700 mm3 (1500-4500 mm3) 1700 mm3 (1500-4500 mm3) 3400 mm3 3300 mm3
T lymphocytes*
T lymphocytes,
CD31
84% (52% to 78%) NA 66% (63% to 84%) 70% (65% to 80%) NA NA
T lymphocytes,
CD41
51% (25% to 48%) NA 42% (33% to 57%) 33%Y (40% to 50%) NA NA
T lymphocytes,
CD81
26% (9% to 35%) NA 20% (14% to 39%) 32% (26% to 30%) NA NA
CD4/CD8 ratio 1.96 (0.9-3.4) NA 2.1 (1.5-2) 1.03Y (1.5-2) NA NA
T lymphocytes,
CD41
1110 mm3 (400-2100 mm3) NA 715.68 mm3 (400-1535 mm3) 551.1 mm3 (500-800 mm3) NA NA
T lymphocytes,
CD81
570 mm3 (200-1200 mm3) NA 340.8 mm3 (139-1015 mm3) 534.4 mm3 (250-800 mm3) NA NA
NK cells, CD561 5%Y (6% to 27%) NA 8% (7% to 21%) 5% (5% to 10%) NA NA
B lymphocytes*
Proportion of B
lymphocytes,
CD191
8% (8% to 24%) NA 19% (7% to 22%) 19% (10% to 15%) 12%Y (13% to 27%) 5%Y (13%
to 27%)
Total B lympho-
cytes, CD191
160 mm3Y (200-600 mm3) NA NA NA 408 mm3 (270-860 mm3) 165 mm3Y
(270-860 mm3)
CD2111CD241/
CD191
NA NA NA NA 84% 84%
CD211CD2411/
CD191
NA NA NA NA 1.7% 1.2%
CD212CD242/
CD191
NA NA NA NA 5% 5%
CD271/CD191 NA NA NA NA 31% (>10) 16% (>10)
CD271IgD1/
CD191 (mar-
ginal zone)
15% (6% to 29%) NA NA NA 21% 8%
IgM1IgD1/CD191 NA NA NA NA 78% 63%
IgM1IgD1/
CD271CD191
NA NA NA NA 63% 37%
IgM1IgD2/
CD271CD191
NA NA NA NA 16% 8%
IgM2IgD2/
CD271CD191
NA NA NA NA 17% (>10) 46% (>10)
CD212CD382/
CD191
NA NA NA NA 5% 3.7%
IgD1CD272
(naive)
78% (47% to 84%) NA NA NA NA NA
(Continued)
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TABLE E3. (Continued )
P6 (classical CdLS) P8 (mild CdLS) P10 (mild CdLS) P11 (mild CdLS) SMC1A-1 SMC1A-2
IgD2CD271
(switched mem-
ory)
4%Y (8% to 29%) NA NA NA NA NA
IgM2CD381
(plasmablasts)
1% (0% to 3.2%) NA NA NA NA NA
IgM11CD3811
(transitional)
<0.5% (<1) NA NA NA NA NA
B2CD212CD382
(CD21 low)
1% (<4) NA NA NA NA NA
B-cell
proliferation
NA NA NA NA NA Normal
Immunoglobulins*
IgM 1.71 g/L (0.27-2.1 g/L) 0.59 g/L (0.27-2.1 g/L) 56.2 mg/dLY (60-263 mg/dL) 65.4 mg/dL (50-268 mg/dL) NA 1.47 g/L
(0.53-1.62 g/L)
IgG 14.5 g/L (6.1-14.5 g/L) 9.65 g/L (6.1-14.5 g/L) 754 mg/dLY (768-1632 mg/dL) 825 mg/dL (768-1632 mg/dL) NA 14.97 g/L
(6.55-12 g/L)
IgA 2.82 g/L (0.7-3.65 g/L) 0.98 g/L (0.5-2.3 g/L) 63.5 mg/dLY (68-378 mg/dL) 180 mg/dL (68-378 mg/dL) NA 1.89 g/L
(0.5-2.03 g/L)
Immunoglobulin
switching
NA NA NA NA NA Positive but weak
Specific immunoglobulins
S-Difteri-ak (IgG) NA 0.2 IE/mL (0.01-3.0 IE/mL) NA NA NA NA
S-Tetanus-ak (IgG) NA 0.25 IE/mL (0.09-12.87 IE/mL) NA NA NA NA
S-Tetanus-ak
(IgG1)
0.75 mg/LY (4.9-180 mg/L) 2.9 mg/L (0.9-228.5 mg/L) NA NA NA NA
S-Haemophilus-ak
(IgG)
NA 0.14 mg/LY (0.15-29.5 mg/L) NA NA NA NA
S-Pneumokock-ak
(IgG2)
NA 11 mg/L (0.8-122.4 mg/L) NA NA NA NA
S-Pneumokock-ak
(IgG)
NA 25 mg/L (9.2-225.9 mg/L) NA NA NA NA
NA, Not analyzed; NS, nonstimulated; TH3, thymidine incorporation.
*Normal range from the immunologic center where the measurement was taken is indicated in parentheses. Values less than the normal range are indicated in boldface.
Measured after stimulation with IL-4, CD40L, CD40L plus IL-4, NS-BAFF_TH3, BAFF_TH3, BAFF 1 m_TH3 or CpG 1 m_TH3.
Measured after stimulation with CD40L 1 IL-4 for switching to IgE.
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